A new acid isolated from V. negundo L. inhibits NLRP3 inflammasome activation and protects against inflammatory diseases

Qianqian Di; Xibao Zhao; Jing Lin; Xunwei Li; Xiaoli Li; Haimei Tang; Ruihan Zhang; Weilie Xiao; Weilin Chen

doi:10.3389/fimmu.2023.1174463

Frontiers in Immunology (Apr 2023)

A new acid isolated from V. negundo L. inhibits NLRP3 inflammasome activation and protects against inflammatory diseases

Qianqian Di,
Xibao Zhao,
Jing Lin,
Xunwei Li,
Xiaoli Li,
Haimei Tang,
Ruihan Zhang,
Weilie Xiao,
Weilin Chen

Affiliations

Qianqian Di: Guangdong Provincial Key Laboratory for Regional Immunity and Diseases, Institute of Biological Therapy, Department of Immunology, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China
Xibao Zhao: Guangdong Provincial Key Laboratory for Regional Immunity and Diseases, Institute of Biological Therapy, Department of Immunology, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China
Jing Lin: Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Characteristic Plant Extraction Laboratory, Yunnan Provincial Center for Research & Development of Natural Products, State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Pharmacy and School of Chemical Science and Technology, Yunnan University, Kunming, China
Xunwei Li: Guangdong Provincial Key Laboratory for Regional Immunity and Diseases, Institute of Biological Therapy, Department of Immunology, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China
Xiaoli Li: Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Characteristic Plant Extraction Laboratory, Yunnan Provincial Center for Research & Development of Natural Products, State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Pharmacy and School of Chemical Science and Technology, Yunnan University, Kunming, China
Haimei Tang: Guangdong Provincial Key Laboratory for Regional Immunity and Diseases, Institute of Biological Therapy, Department of Immunology, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China
Ruihan Zhang: Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Characteristic Plant Extraction Laboratory, Yunnan Provincial Center for Research & Development of Natural Products, State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Pharmacy and School of Chemical Science and Technology, Yunnan University, Kunming, China
Weilie Xiao: Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, Yunnan Characteristic Plant Extraction Laboratory, Yunnan Provincial Center for Research & Development of Natural Products, State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, School of Pharmacy and School of Chemical Science and Technology, Yunnan University, Kunming, China
Weilin Chen: Guangdong Provincial Key Laboratory for Regional Immunity and Diseases, Institute of Biological Therapy, Department of Immunology, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China

DOI: https://doi.org/10.3389/fimmu.2023.1174463
Journal volume & issue: Vol. 14

Abstract

Read online

The NLRP3 inflammasome plays a critical role in the innate immune response, and its excessive activation will cause pyroptotic cell death and be associated with the onset of inflammatory diseases. However, NLRP3 inflammasome targeting therapies are still to be implemented in the clinic setting. Here, we first isolated, purified and characterized a novel Vitenegu acid from V. negundo L. herb that specifically inhibits NLRP3 inflammasome activation, without affecting NLRC4 or AIM2 inflammasomes. Vitenegu acid blocks the oligomerization of NLRP3, thus inhibiting NLRP3 inflammasome assembly and activation. In vivo data show that Vitenegu acid exerts therapeutic effects on NLRP3 inflammasome-dependent inflammation. Taken together, our results suggest that Vitenegu acid is a candidate therapeutic agent for treating NLRP3 inflammasome related diseases.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords